Meta Analysis of DHA and EPA Supplementation on Cardiovascular Outcomes and Atrial Fibrillation Risk

Area of Science:

• Cardiology
• Nutritional Science
• Pharmacology

Background:

• Cardiovascular diseases (CVD) are a leading global health burden.
• Omega-3 fatty acids (EPA and DHA) are studied for cardioprotection, but results are debated.
• Heterogeneity in omega-3 formulations, doses, and patient groups complicates findings.

Purpose of the Study:

• To evaluate the effect of combined EPA + DHA supplementation on MACE and AF in patients with established CVD.
• To synthesize evidence from randomized controlled trials (RCTs) for secondary prevention and perioperative settings.
• To identify potential benefits or limitations of omega-3s in diverse cardiovascular patient populations.

Main Methods:

• Systematic literature search of Embase, PubMed/MEDLINE, Scopus, and Web of Science (2010-2021).
• Meta-analysis of 25 RCTs (25,578 patients) using a random-effects model.
• Cochrane RoB 2 tool assessed study quality; RevMan v5.3 used for data synthesis.

Main Results:

• No significant reduction in MACE (p=0.396) or AF/POAF incidence (p=0.187) with combined EPA + DHA.
• A trend toward AF reduction was observed but did not reach statistical significance.
• Neutral findings may be due to moderate doses, limited subgroup data, and high background medical therapy.

Conclusions:

• Moderate-dose combined EPA + DHA does not broadly reduce MACE or AF risk in heterogeneous CVD populations.
• Recent studies suggest high-dose purified EPA monotherapy may benefit high-metabolic-risk subgroups.
• Future research needs to stratify by formulation, dose, metabolic status, and comorbidities for targeted roles.